Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $39.2 million versus the consensus estimate of $40.61 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Wayfair Sees High Single Digit 3Q Growth - Conf Call
• Standard Motor Products (SMP) Declares $0.33 Quarterly Dividend; 3.4% Yield
• Grainger (GWW) Tops Q2 EPS by 73c ; Offers Guidance